TradingKey

Más Datos de Vyne Therapeutics Inc Compañía

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Información de la empresa

Símbolo de cotizaciónVYNE

Nombre de la empresaVyne Therapeutics Inc

Fecha de salida a bolsaJan 25, 2018

Director ejecutivoMr. David Domzalski

Número de empleados13

Tipo de seguridadOrdinary Share

Fin del año fiscalJan 25

Dirección685 Route 202/206 N., Suite 301

CiudadBRIDGEWATER

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal08807

Teléfono18007757936

Sitio Webhttps://vynetherapeutics.com/

Símbolo de cotizaciónVYNE

Fecha de salida a bolsaJan 25, 2018

Director ejecutivoMr. David Domzalski

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

116.19K

-2.86%

Mr. Patrick G. Lepore

Lead Independent Director

51.47K

--

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

42.30K

-5.45%

Mr. Steven L. Basta

Independent Director

7.45K

--

Mr. Anthony Bruno

Independent Director

--

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

--

Ms. Sharon Barbari

Independent Director

--

Dr. Christine Borowski, Ph.D.

Independent Director

--

Mr. David Domzalski

President, Chief Executive Officer, Director

--

Ms. Elisabeth A. Sandoval Little

Independent Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

116.19K

-2.86%

Mr. Patrick G. Lepore

Lead Independent Director

51.47K

--

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

42.30K

-5.45%

Mr. Steven L. Basta

Independent Director

7.45K

--

Mr. Anthony Bruno

Independent Director

--

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

--

Desglose de ingresos

Divisa: USDActualizado: dom., 6 de jul

FY2024

FY2023

FY2022

FY2021

FY2020

Por negocioUSD

Nombre

Ganancia

Proporción

Royalty revenues

501.00K

0.00%

Sin datos

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Royalty revenues

501.00K

0.00%

Estadísticas de accionistas

Actualizado: dom., 1 de jun

Accionistas

Tipos de accionistas

Accionistas

Proporción

Eventide Asset Management, LLC

8.37%

Access Industries, Inc.

6.70%

Citadel Advisors LLC

6.60%

Acorn Capital Advisors, LLC

4.72%

Delaware Street Capital, L.L.C.

4.18%

Other

69.43%

Accionistas

Proporción

Eventide Asset Management, LLC

8.37%

Access Industries, Inc.

6.70%

Citadel Advisors LLC

6.60%

Acorn Capital Advisors, LLC

4.72%

Delaware Street Capital, L.L.C.

4.18%

Other

69.43%

Tipos de accionistas

Accionistas

Proporción

Hedge Fund

26.69%

Investment Advisor

17.90%

Corporation

6.70%

Individual Investor

2.22%

Private Equity

1.54%

Investment Advisor/Hedge Fund

1.05%

Research Firm

0.32%

Venture Capital

0.20%

Other

43.37%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

83

9.44M

56.62%

-1.32M

2025Q1

81

9.36M

56.20%

-1.38M

2024Q4

92

9.37M

63.49%

-533.87K

2024Q3

88

8.98M

61.30%

-594.32K

2024Q2

89

9.65M

66.73%

+287.65K

2024Q1

92

9.64M

67.66%

+101.95K

2023Q4

101

10.22M

72.71%

+4.63M

2023Q3

117

471.27K

14.37%

-340.06K

2023Q2

135

501.83K

15.37%

-314.68K

2023Q1

168

461.83K

16.95%

-412.21K

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Eventide Asset Management, LLC

1.39M

8.37%

--

Mar 31, 2025

Access Industries, Inc.

1.12M

6.7%

--

Feb 14, 2025

Citadel Advisors LLC

1.10M

6.6%

-130.13K

-10.58%

Mar 31, 2025

Acorn Capital Advisors, LLC

785.94K

4.72%

+328.97K

+71.99%

Mar 31, 2025

Delaware Street Capital, L.L.C.

696.47K

4.18%

--

Sep 30, 2024

Dafna Capital Management, LLC

636.10K

3.82%

+636.10K

--

Mar 31, 2025

The Vanguard Group, Inc.

475.65K

2.85%

+521.00

+0.11%

Mar 31, 2025

Exome Asset Management LLC

462.80K

2.78%

+109.37K

+30.94%

Mar 31, 2025

Palo Alto Investors LP

445.43K

2.67%

--

Mar 31, 2025

Adage Capital Management, L.P.

344.13K

2.06%

+190.00K

+123.27%

Mar 31, 2025

ETFs relacionados

Actualizado: sáb., 2 de ago

Nombre

Proporción

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Feb 10, 2023

Merger

18<1

Feb 10, 2023

Merger

18<1

Feb 10, 2023

Merger

18<1

Feb 10, 2023

Merger

18<1

Feb 12, 2021

Merger

4<1

Feb 12, 2021

Merger

4<1

Fecha

Tipo

Relación

Feb 10, 2023

Merger

18<1

Feb 10, 2023

Merger

18<1

Feb 10, 2023

Merger

18<1

Feb 10, 2023

Merger

18<1

Feb 12, 2021

Merger

4<1

Feb 12, 2021

Merger

4<1

Feb 12, 2021

Merger

4<1

Feb 12, 2021

Merger

4<1

Vyne Therapeutics Inc

0.370USD

Vyne Therapeutics Inc

0.370

Descripción general

Compañía

Finanzas